Farther Finance Advisors, LLC

Position in PTGX — Protagonist Therapeutics, Inc

CIK 1992825 SAN FRANCISCO, CA

Position in PTGX

as of Jun 30, 2026 · filed Jul 17, 2026 Compact

Position Value

$54,180

+$19,082 QoQ

Shares Held

442

+32.7% QoQ

Ownership

0.001%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#278

of 341 holders

Holding Since

Dec 2023

11 quarters on record

Voting authority Sole 0% Shared 0% None 100%

Healthcare · as of Jun 30, 2026

Farther Finance Advisors, LLC holds $15,699,251 across 282 Biotechnology names. PTGX ranks #49 (0.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	4,922	$2,444,905
2	MRNA	Moderna, Inc.	15,429	$1,080,492
3	ARWR	Arrowhead Pharmaceuticals, Inc.	12,088	$985,292
4	HALO	Halozyme Therapeutics, Inc.	11,241	$879,833
5	EXEL	Exelixis, Inc.	14,171	$771,044
6	REGN	Regeneron Pharmaceuticals, Inc.	1,075	$670,305
7	VKTX	Viking Therapeutics, Inc.	15,171	$591,820
8	BMRN	Biomarin Pharmaceutical Inc	7,871	$450,378

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$54,180	442	+32.7%	Shares	Sole	2026-07-17
2026-03-31	$35,098	333	+12.1%	Shares	Sole	2026-04-07
2025-12-31	$25,939	297	+110.6%	Shares	Sole	2026-01-23
2025-09-30	$9,366	141	+51.6%	Shares	Sole	2025-10-14
2025-06-30	$5,140	93	-76.1%	Shares	Sole	2025-07-11
2025-03-31	$18,812	389	+784.1%	Shares	Sole	2025-04-14
2024-12-31	$1,698	44	0.0%	Shares	Sole	2025-02-10
2024-09-30	$1,980	44	-2.2%	Shares	Sole	2024-10-29
2024-06-30	$1,559	45	+12.5%	Shares	Sole	2024-07-31
2024-03-31	$1,157	40	0.0%	Shares	Sole	2024-05-14
2023-12-31	$917	40	—	Shares	Sole	2024-02-15
No filing history on record for this holder in this stock.